Seqens Seqens

X

Find Radio Compass News for MolPort-000-917-894

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
98
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

USP

JP

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • CAPSULE;ORAL - 20MG
  • CAPSULE;ORAL - 40MG

https://www.globenewswire.com//news-release/2024/01/16/2809672/0/en/ANI-Pharmaceuticals-Announces-the-FDA-Approval-and-Launch-of-Indomethacin-Oral-Suspension-USP.html

GLOBENEWSWIRE
16 Jan 2024

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-6-2023-46648.pdf

FDA
06 Dec 2023

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfda-nod-for-generic-rheumatoid-arthritis-treatment-drug/articleshow/102388054.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

ECONOMIC TIMES
03 Aug 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216184

FDA
02 Aug 2023

http://www.pharmabiz.com/NewsDetails.aspx?aid=145111&sid=2

PHARMABIZ
08 Jan 2022

https://www.axios.com/indocin-suppository-drug-prices-assertio-zyla-egalet-3278e307-d900-475c-92c9-8e5ff828a7da.html

Bob Herman AXIOS
19 Oct 2021

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-8-2018-1533711950.pdf

FDA
08 Aug 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202711

FDA
27 Sep 2017

http://www.moneycontrol.com/news/business/zydus-gets-usfda-nod-for-anti-inflammatory-drug-2398997.html

MONEYCONTROL
26 Sep 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205215

FDA
29 Aug 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203501

FDA
26 Jun 2017

http://www.biospace.com/News/philadelphia-drugmaker-iroko-pharma-pink-slips/458539/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

Alex Keown BIOSPACE
02 Jun 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204853

FDA
08 May 2017

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-8-2017-1488980224.pdf

FDA
08 Mar 2017

http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204243

FDA
27 Dec 2016

http://www.in-pharmatechnologist.com/Ingredients/Merck-launches-HME-excipient-with-high-API-loading-capacity

IN PHARMATECHNOLOGIST
07 Dec 2016

http://www.reuters.com/article/us-health-nsaids-heart-failure-idUSKCN12K2J1

REUTERS
21 Oct 2016

http://www.pharma-excipients.ch/2016/03/13/novel-tablet-formulation-of-amorphous-indomethacin-using-wet-granulation-with-a-high-speed-mixer-granulator-combined-with-porous-calcium-silicate/

PHARMA-EXCIPIENTS
14 Mar 2016

http://www.pharma-excipients.ch/2016/03/12/the-effect-of-surfactants-on-the-dissolution-behavior-of-amorphous-formulations/

PHARMA-EXCIPIENTS
14 Mar 2016

http://www.livemint.com/Companies/EkQlcDN8hsifR0kqHfgHTP/SA-govt-warns-Ranbaxy-seeks-detailed-report-on-drug-recall.html

LIVE MINT
19 Feb 2016

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-life-gets-usfda-nod-for-indomethacin-capsules/articleshow/49254734.cms?

THE ECONOMIC TIMES
06 Oct 2015
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY